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Abstract 
Colorectal carcinoma (CRC) is the third most common cancer in men and the 
second most common cancer in women across the world. Most CRCs occur 
sporadically, but in 15-35% of cases, hereditary factors are important. Some 
patients with an inherited predisposition to CRC will be diagnosed with a ‘genetic 
polyposis syndrome’ such as Familial Adenomatous Polyposis (FAP), MUTYH-
Associated Polyposis (MAP), Polymerase Proofreading Associated Polyposis 
(PPAP), NTHL1-Associated Polyposis, MSH3-Associated Polyposis or a 
hamartomatous polyposis syndrome. Individuals with >/= 10 colorectal polyps have 
traditionally been referred for genetic diagnostic testing aiming to identify APC and 
MUTYH mutations which cause FAP and MAP respectively. Mutations are found in 
most patients with >100 adenomas but in only a minority of those with 10-100 
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adenomas.  The reasons that diagnostic laboratories are not identifying pathogenic 
variants include mutations occurring outside of the open reading frames of genes, 
individuals exhibiting generalised mosaicism and the involvement of additional 
genes.  It is important to identify patients with an inherited polyposis syndrome, and 
to define the mutations causing their polyposis, so that the individuals and their 
relatives can be managed appropriately. 
1. Introduction 
 Across the globe, colorectal carcinoma (CRC) is the third most common 
cancer in men and the second most common cancer in women (Ferlay et al 2013). 
An individual’s lifetime risk of developing CRC is 5%, but this figure increases 
dramatically with age (reviewed in Fodde 2002). The incidence of CRC is generally 
high in developed countries, with a 20-fold difference in incidence rates between 
high- and low-risk geographical areas (reviewed in Fodde 2002). The difference is 
thought to largely result from environmental factors, in particular differences in diet 
(Fodde 2002). 
 The majority of CRCs occur sporadically, but in 15-35% of patients, 
hereditary factors are important (reviewed in Mishra and Hall 2012; Burt 2007). In 
approximately 5% of cases, the disease is caused by a highly penetrant dominantly 
inherited syndrome (reviewed in Mishra and Hall 2012). The most common is Lynch 
Syndrome, due to inherited defects in the mismatch repair (MMR) system. This 
accounts for 2-5% of cases of CRC (reviewed in Mishra and Hall 2012). Familial 
Adenomatous Polyposis (FAP), due to germline mutations in the APC gene, is 
responsible for <1% of the disease burden and non-syndromic familial presentations 
comprise 20% of cases (reviewed in Mishra and Hall 2012).    
 CRCs result from the progressive accumulation of genetic and epigenetic 
alterations which cause normal colonic epithelium to transform into adenocarcinoma 
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(Grady and Carethers 2008). Recent work based on gene expression profiling 
(Guinney et al 2015) suggests that CRC can be classified into 4 molecular 
subtypes: MSI Immune, Canonical, Metabolic and Mesenchymal. However, the 
traditional approach has been to categorise  tumors into 3 groups: those with 
chromosomal instability (CIN), those with microsatellite instability (MSI) and those 
with a hypermethylated phenotype (CpG Island Methylator Phenotype or ‘CIMP’). 
There is considerable overlap between the latter two groups.  
1.1 Chromosomal Instability (CIN), APC and the Wnt-
Pathway 
 The vast majority of CRCs develop from pre-existing adenomas. Such 
lesions are characterised by chromosomal instability, which is seen in 80-85% of 
colorectal  tumors (reviewed in Grady and Carethers 2008). There are certain key 
genetic mutational events which occur, allowing the progression from normal 
epithelium, to dysplasia, and finally invasive malignancy. The loss of adenomatous 
polyposis coli (APC) gene function seems to be the initiating event, followed by 
mutations in KRAS, SMAD4 and p53 (Fodde 2002). In keeping with Knudson’s two 
hit hypothesis of tumorigenesis, two mutational events are required to knock out the 
functioning of a tumor suppressor gene (Knudson 1971), whilst activation of an 
oncogene requires only one mutation. 
1.1.1 Adenomatous Polyposis Coli (APC) 
 The APC gene is found on chromosome 5 (5q21). It consists of 8535 
coding base pairs, encoding a 2843 amino acid multidomain protein. Exon 15 is 
responsible for more than 75% of the coding sequence of the gene and is the most 
common site for germline and somatic mutations (reviewed in Fearnhead et al 2002; 
reviewed in Fearnhead et al 2001). 95% of CRC-associated APC mutations are 
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nonsense or frameshift mutations, creating a truncated protein with abnormal 
function (Bodmer 1999).  
 The APC protein is a 312kDa tumor suppressor, which is involved in many 
cellular processes including intercellular adhesion, signal transduction, proliferation, 
apoptosis and migration. One of its major roles is in regulating cytoplasmic levels of 
β-catenin, thus negatively regulating Wnt signalling (Mishra and Hall 2012; reviewed 
in Fearnhead et al 2002; Fodde 2002; Fearnhead et al 2001). 
1.1.2 The Wnt Pathway 
 The Wnt proteins are a family of signalling proteins which are involved in 
developmental events during embryogenesis and in adult tissue homeostasis 
(Logan and Nusse 2004). They have multiple effects within a cell, including 
triggering cell division, cell fate specification and differentiation (Logan and Nusse 
2004).  
 Wnt proteins bind to Frizzled/ low density lipoprotein receptor-related 
proteins, which are found on cell surface membranes (Logan and Nusse 2004). This 
transduces a signal to intracellular proteins, including Dishevelled (Dsh), Glycogen 
Synthase Kinase-3β (GSK-3), AXIN, APC and β-catenin (Logan and Nusse 2004). 
In the absence of Wnt signalling, β-catenin levels are usually low: a complex 
composed of GSK-3, APC and AXIN targets it for ubiquitin-mediated degradation 
(Logan and Nusse 2004; reviewed in Fearnhead et al 2002; reviewed in Fearnhead 
et al 2001). When cells receive Wnt signals, the degradation pathway is inhibited. 
This allows β-catenin to accumulate in the cytoplasm and nucleus. In the nucleus, it 
complexes with one of the T cell factor (TCF) or lymphoid enhancer factor (LEF) 
transcription factors, to initiate transcription of a range of genes, including c-myc 
and cyclin D1 (Logan and Nusse 2004; reviewed in Fearnhead et al 2002; reviewed 
in Fodde 2002; reviewed in Fearnhead et al 2001). Myc and cyclin D1 are both 
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relevant to  tumorigenesis as they have roles in proliferation, apoptosis and cell-
cycle progression (reviewed in Fodde 2002).  
 In the normal intestinal epithelium, nuclear β-catenin expression is higher in 
the proliferative component, and APC levels are higher in post-replicative cells 
(reviewed in Fodde 2002). These findings support β-catenin signalling having a role 
in maintaining stem cell properties and controlling differentiation in the bowel 
(reviewed in Fodde 2002). As cells move along the crypt-villous axis, increasing 
levels of APC counteract β-catenin signalling and allow differentiation to occur 
(reviewed in Fodde 2002). APC mutations hence allow increased numbers of stem 
cells and reduced cellular differentiation (Fodde 2002). 
 In addition to their roles in the initial stages of the adenoma-carcinoma 
sequence, APC mutations remain important throughout malignant progression. 
Nuclear β-catenin staining strongly correlates with  tumor size and dysplasia, and 
high levels of nuclear β-catenin have been found at the invasive fronts of 
adenocarcinomas (reviewed in Fodde 2002). The APC protein is also involved in 
chromosomal stability at mitosis: it has an EB1-binding domain in its C-terminal end, 
which associates with the growing ends of cytoplasmic and spindle microtubules, as 
well as centrosomes. APC mutant cells are hence characterised by chromosomal 
instability which is observed in the majority of CRCs (reviewed in Grady and 
Carethers 2008; reviewed in Fodde 2002). 
 APC mutations can therefore be seen to have a key role in both initiating 
and promoting CRC: activation of the Wnt pathway affects cell proliferation, 
apoptosis, and possibly differentiation of intestinal stem cells (Fodde 2002) and at 
later stages of carcinogenesis, CIN resulting from APC mutations can accelerate  
tumor progression (Fodde 2002). 
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1.1.3 KRAS, SMAD4 and P53 
 Further genes involved in colorectal tumorigenesis include KRAS, SMAD4, 
and p53. The importance of ras gene mutations in colorectal carcinogenesis was 
first reported in 1987 (Bos et al 1987; Forrester et al 1987). The K-ras oncogene 
has been found to be mutated in 10-15% of adenomas <1cm, and in 30-60% of 
adenomas >1cm and carcinomas (reviewed in Brink et al 2003; reviewed in Fearon 
and Vogelstein 1990). The gene encodes a 21kDA protein located in the inner 
plasma membrane, with intrinsic GTPase activity. It is involved in the transduction of 
mitogenic signals (reviewed in Brink et al 2003). It is activated by a diverse 
spectrum of extracellular stimuli, such as growth factors, cytokines and hormones 
(reviewed in Brink et al 2003; Shields et al 2000). Once activated, it stimulates a 
multitude of downstream signalling cascades, including the Raf serine/threonine 
kinases, phosphoinositide 3-kinases (PI3Ks) and a family of GDP-GTP exchange 
factors (reviewed in Shields et al 2000).  
 Mutant KRAS has impaired GTPase activity, meaning that it is 
constitutively active (reviewed in Brink et al 2003). This can cause uncontrolled cell 
growth and proliferation. A KRAS mutation in a colonic epithelial cell which already 
has APC mutations results in a clonal expansion and increased risk of progression 
to cancer (reviewed in Vogelstein and Kinzler 2004). 
 The SMAD4 gene is on chromosome 18q. It was first identified as a tumor 
suppressor gene in pancreatic cancer in 1996 (Hahn et al 1996). SMAD4 mediates 
the TGFβ signalling pathway to suppress epithelial growth (reviewed in Miyaki and 
Kuroki 2003). The SMAD4 protein acts as a trimer and forms complexes with 
additional SMAD proteins: receptor-phosphorylated SMAD2 and SMAD3 
(Woodford-Richens et al 2001). These complexes then translocate from the 
cytoplasm to the nucleus and associate with DNA binding factors to facilitate the 
transcription of target genes, including cyclin-dependent kinase inhibitors such as 
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p15(ink4B) and the inhibitory SMAD7 (Woodford-Richens et al 2001). Loss of 
SMAD4 function may result in the loss of transcription of genes necessary for cell-
cycle control (Woodford-Richens et al 2001). Cells may therefore become TGF-β 
resistant and escape from TGF-β-mediated growth control and apoptosis 
(Woodford-Richens et al 2001). SMAD4 is mutated in a significant proportion of 
colorectal tumors, with the frequency of mutational events increasing with the 
progression of carcinogenesis: it is mutated in 0% of adenomas, 10% of 
‘intramucosal carcinomas’, 7% of carcinomas without metastases and 35% of 
carcinomas with distant metastases (reviewed in Miyaki and Kuroki 2003).  
 In 1988, it was reported that 73% of CRCs, 47% of ‘advanced adenomas’ 
and 11-13% of ‘early stage adenomas’ had a deletion of part of chromosome 17 
(Vogelstein et al 1988). This region was subsequently shown to include the p53 
gene (17p13.1) (Baker et al 1989). The p53 protein is a transcription factor which 
has a vital role in maintaining genomic stability (reviewed in Sarasqueta et al 2013). 
Following DNA damage, p53 activation causes arrest of the cell cycle to allow DNA 
repair (reviewed in Sarasqueta et al 2013). If the damage is too extensive, p53 can 
drive a cell towards senescence or apoptosis (reviewed in Sarasqueta et al 2013; 
reviewed in Vogelstein and Kinzler 2004). The functional loss of p53 is a key event 
in the malignant progression of a colorectal adenoma to CRC (reviewed in Iacopetta 
2003; Vogelstein et al 1988).  
1.2 Microsatellite Instability (MSI) 
 The human mismatch repair system (MMR) involves 7 key genes: hMSH2, 
hMSH6, hMSH3, hMLH1, hPMS1, hPMS2 and hMLF3. Their protein products are 
able to recognise and repair nucleotide mismatches, which have escaped the 
normal editing function of DNA polymerase (reviewed in Grady and Carethers 
2008). If such mismatches are not repaired, nucleotide transitions or transversions 
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result, allowing potentially oncogenic mutations to occur more frequently, leading to 
a ‘hypermutable phenotype’ (reviewed in Grady and Carethers 2008).  
 Lynch Syndrome (LS) is an autosomal dominant (AD) disease, which 
accounts for approximately 5% of cases of CRC (reviewed in Mishra and Hall 2012). 
Patients also have an inherited predisposition to a range of other malignancies, in 
particular endometrial carcinoma (Lynch et al 2015). LS occurs due to inherited 
mutations of hMSH2, hMSH6, hMLH1 or hPMS2 (reviewed in Grady and Carethers 
2008). In 15-20% of sporadic colon cancers, inactivation of the mismatch repair 
(MMR) system occurs, either though methylation of MLH1 or point mutations in 
MLH1/MSH2/other members of the MMR family (reviewed in Grady and Carethers 
2008). This leads to microsatellite instability (MSI).  
 It is thought that certain key tumor suppressor genes drive the 
pathogenesis of MSI  tumors, and these are different to those which are mutated in 
CIN  tumors (reviewed in Grady and Carethers 2008). In around 85% of colorectal 
tumors with MSI, a repeat of 10 adenines undergoes a frameshift mutation in the 
TGFBR2 gene. This allows tumor cells to escape the growth suppressing effects of 
TGF-β1 (reviewed in Grady and Carethers 2008). Another gene commonly mutated 
in MSI CRC is BAX, which plays a role in apoptosis. It is mutated in 50% of MSI 
CRC, allowing immortalisation of cells (reviewed in Grady and Carethers 2008). 
Interestingly, frameshift mutations within coding mononucleotide repeats are also 
seen in APC (reviewed in Lynch et al 2015). 
 MSI CRCs tend to have a certain clinical and pathological phenotype. They 
generally occur in the right side of the colon, and microscopically they have a 
mucinous appearance with large numbers of  tumor-infiltrating lymphocytes 
(reviewed in Grady and Carethers 2008). 
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1.3 CpG Island Methylator Phenotype (CIMP) 
Epigenetic regulation of gene expression can be achieved through methylation of 
CpG islands found in gene promoters, causing silencing of the downstream gene. 
Such silencing of  tumor suppressors and/or DNA repair genes is a common feature 
of human neoplasia (reviewed in Hughes et al 2012). Widespread CpG island 
promoter methylation is referred to as the CpG island methylator phenotype (CIMP) 
and was first described in 1999 (Toyota et al 1999). The cause of CIMP remains to 
be elucidated but may potentially result from aberrant de novo methylation or 
through the loss of protection against de novo methylation (reviewed in Toyota et al 
1999). Environmental factors, such as anthropometry and physical activity, smoking 
and alcohol may also play a role (reviewed in Hughes et al 2012). 
 CRC which exhibit CIMP are thought to arise via the ‘serrated pathway of 
neoplasia’. The precursor lesions are hyperplastic polyps, rather than adenomas, 
and an early event is a mutation of the BRAF oncogene (reviewed in Guarinos et al 
2012). BRAF is a component of the MAPK signalling pathway. The pathway 
involves activation of cell membrane signalling molecules with subsequent 
stimulation of cytoplasmic protein kinases (Seger and Krebs 1995). The transmitted 
signals eventually activate cellular processes such as proliferation, differentiation 
and development (Seger and Krebs 1995). Activating mutations of BRAF increase 
its kinase activity, which drives the proliferation of malignant cells (reviewed in 
Bollag et al 2012). 
 Most CIMP CRCs have epigenetic silencing of MLH1, leading to 
microsatellite instability (reviewed in Hughes et al 2012), and may have silencing of  
tumor suppressor genes such as p16 (Toyota et al 1999). 
 Typically, CIMP  tumors are associated with older age, female sex and 
occurrence in the right side of the bowel (reviewed in Hughes et al 2012), as is seen 
with MSI CRC. 
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2. The Colorectal Polyposis Syndromes 
 Colorectal polyps are masses of tissue which are found projecting from the 
mucosa of the large bowel. They are classified according to their microscopic 
appearance, and include adenomas, hyperplastic polyps and hamartomatous 
polyps (Figure 1). Most polyps occur sporadically, but some are seen as part of a 
genetic ‘polyposis syndrome’ (Figure 2). Colorectal polyps are benign but are 
clinically significant as they may confer a risk of malignancy. 
 
[Insert Figure 1] 
Figure 1:  Haematoxylin and Eosin (H&E) microscopic images of colorectal 
polyps 
A:  Tubular adenoma with low grade dysplasia 
B:  Hyperplastic polyp: note the presence of glands in the centre of the image 
with a serrated/ ‘tooth like’ appearance 
C:  A Peutz-Jegher’s polyp.  The glands are separated by bundles of smooth 
muscle 
D:  A juvenile polyp.  Cystically dilated glands are present in an odematous 
and inflamed stroma 
 
Image from Short et al 2015 
 
[Insert Figure 2] 
Figure 2:  Diagram illustrating relationships between genes and signalling 
pathways involved in inherited colorectal cancer syndromes.  Key: FAP: 
Familial Adenomatous Polyposis; HMPS:  Hereditary Mixed Polyposis 
Syndrome; JPS: Juvenile Polyposis Syndrome; LS: Lynch Syndrome; MAP: 
MUTYH-Associated Polyposis; NTHL1: NTHL1-Associated Polyposis; PPAP: 
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Polymerase Proofreading Associated Polyposis; PJS: Peutz Jegher’s 
Syndrome. 
 
Image from Short et al 2015 
 
2.1 Colorectal Adenomas 
 Colorectal adenomas are common. They are found in between 1.72% and 
63% of autopsies (Pendergrass et al 2008; Paspatis et al 2001; Correa et al 1977; 
Arminski and McLean 1964; Chapman 1963). In asymptomatic patients undergoing 
colonoscopies, adenoma prevalence is between 6.3% and 41% (Chung et al 2010; 
Rundle et al 2008; Lin et al 2006; Strul et al 2006; Soon et al 2005; reviewed in 
Giacosa 2004; Yamaji et al 2004; DiSario et al 1991). They occur more frequently in 
males than in females, and their prevalence increases with age (Chung et al 2010; 
Pendergrass et al 2008; Lin et al 2006; Strul et al 2006; Soon et al 2005; Yamaji et 
al 2004; Paspatis et al 2001; DiSario et al 1991; Correa et al 1977; Chapman 1963). 
 The significance of colorectal adenomas is that they are pre-malignant 
lesions. The majority of colorectal CRCs are thought to develop from pre-existing 
adenomas. The probability that an adenoma will become malignant depends upon 
its size, morphology and degree of dysplasia. Large villous lesions harbouring high 
grade dysplasia confer the highest risk (Terry et al 2002; O’Brien et al 1990; Shinya 
and Wolff 1979; Muto et al 1975).  
 Most colorectal adenomas occur sporadically. However, there are 
syndromes of colorectal polyposis, in which patients develop multiple polyps as a 
result of an underlying genetic mutation. These include Familial Adenomatous 
Polyposis (FAP), MUTYH-Associated Polyposis (MAP), Polymerase Proofreading-
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Associated Polyposis (PPAP), NTHL1-Associated Polyposis/CRC and MSH3-
Associated Polyposis/CRC.  
2.1.1 Familial Adenomatous Polyposis (FAP)  
 FAP is a dominantly inherited Mendelian trait, in which patients develop 
hundreds to thousands of colorectal adenomas during adolescence or the third 
decade of life (reviewed in Fearnhead et al 2002; Bodmer 1999). All such patients 
will invariably develop CRC if they are left untreated (Bodmer 1999; reviewed in 
Fearnhead et al 2002).   
 The first case of histologically verified adenomatous polyposis was 
published in 1881 by Sklifasowski (reviewed in Bülow et al 2006). The following year 
Harrison-Cripps described ‘disseminated polypus of the rectum’ in two teenage 
siblings, both of whom had 20-30 colorectal polyps (reviewed in Bülow et al 2006; 
Harrison-Cripps 1882). In the late 1800s there were numerous case reports 
describing patients with multiple colorectal adenomas, and an association with 
colorectal malignancy was noted (reviewed in Bülow et al 2006). In 1925, Lockhart-
Mummery stated that the ‘condition of multiple adenomata was invariably 
antecedent to carcinoma’ and that ‘the condition of multiple adenomata is often 
hereditary in a marked degree’ (Lockhart-Mummery 1925). 
 It is now known that FAP, and an attenuated form of the disease, AFAP, 
are due to germline or somatic mosaic mutations in APC. Over 1500 different 
mutations in APC have been identified to date (Kadiyska et al 2013). The majority of 
mutations are inherited. It used to be thought that approximately one quarter of 
cases occurred de novo (reviewed in Fearnhead et al 2001), but this is an 
overestimate, as this figure included apparent de novo patients who actually had 
MUTYH-Associated Polyposis (MAP). A third of all germline mutations occur at 
codons 1061 and 1309, with the remainder spread relatively uniformly between 
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codons 200 and 1600 (reviewed in Fearnhead et al 2001). The nature of the 
germline mutation determines the nature of the second somatic hit to APC 
(reviewed in Fearnhead et al 2002; reviewed in Fearnhead et al 2001). Germline 
mutations occurring between codons 1194 and 1392 tend to be followed by allelic 
loss of APC as a second hit (loss of heterozygosity, LOH), whereas germline 
mutations lying outside of this region tend to be associated with truncating 
mutations in the mutation cluster region (MCR) between codons 1286 and 1513 
(reviewed in Fearnhead et al 2002). The reason for this may be related to the 
resultant level or functional characteristics of APC protein produced: it is proposed 
that to allow efficient tumorigenesis, the function of APC must be impaired 
sufficiently to allow a certain level of nuclear β-catenin accumulation, but that β-
catenin levels must not be too great, or this can result in apoptosis (Albuquerque et 
al 2002).  
 The incidence of FAP is approximately 1 per 8000, and it accounts for 
around 0.5% - 1% of CRC (Mishra and Hall 2012; reviewed in Fearnhead et al 
2002; reviewed in Bodmer 1999). In addition to colorectal adenomas, FAP patients 
may develop extra-intestinal manifestations of their disease, for example congenital 
hypertrophy of the retinal pigment epithelium (CHRPE), duodenal and peri-
ampullary  tumors, desmoid  tumors, papillary carcinoma of the thyroid, 
medulloblastoma, hepatoblastoma, osteomas and epidermoid cysts (Mishra and 
Hall 2012; reviewed in Fearnhead et al 2002). 
2.1.2 MUTYH-Associated Polyposis (MAP) 
 Prior to 2002, inherited defects of base excision had not been associated 
with any human genetic disorder (Al-Tassan et al 2002). That year, mutations in the 
MUTYH gene were shown to cause an inherited predisposition to colorectal  tumors 
(Al-Tassan et al 2002). 
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 The MUTYH gene is located on the short arm of chromosome 1 (1p32.1-
p34.3) (Poulsen and Bisgaard 2008). It consists of 16 exons and encodes a protein 
of 535 amino acids, the MUTYH glycosylase (Poulsen and Bisgaard 2008). MUTYH 
glycosylase is part of the base excision repair (BER) system. It is involved in 
repairing DNA mismatches occurring as a result of oxidative DNA damage (Mazzei 
et al 2013). Each human cell metabolises approximately 1012 molecules of oxygen 
per day (reviewed in Nohmi et al 2005). About 1% of oxygen metabolism results in 
the production of reactive oxygen species (ROS) which include superoxide, 
hydrogen peroxide, hydroxyl radicals and singlet oxygen (reviewed in Nohmi et al 
2005). ROS can damage DNA, producing 8-hydroxyguanine (8-oxodG). This 
frequently pairs with dAMP. Under normal circumstances, this mispairing would be 
repaired by MUTYH, to create C: 8-oxodG base pairs. Another enzyme, OGG1 will 
then remove the 8-oxodG. Hence the combined effects of MUTYH and OGG1 will 
prevent GC > TA transversions (Mazzei et al 2013). 
 Patients with biallelic germline MUTYH mutations are predisposed to 
mutations in genes including APC and KRAS. The clinical manifestation of this is 
MAP. MAP is an autosomal recessive (AR) disease, in which patients develop 
multiple colorectal adenomas. The mean age of diagnosis is 45-50 years, and 
patients typically have between 10 and 100 polyps (reviewed in Mazzei et al 2013; 
reviewed in Poulsen and Bisgarrd 2008; Croitoru et al 2007; Nielsen et al 2007; 
Gismondi et al 2004; Wang et al 2004; Sampson et al 2003; Sieber et al 2003). 
Some patients do not develop polyps but present with cancer (Farrington et al 2005; 
Wang et al 2004; Enholm et al 2003). Although the majority of polyps are 
adenomas, hyperplastic polyps (HPPs) and sessile serrated adenomas (SSAs) are 
also seen (reviewed in Mazzei et al 2013; Boparai et al 2008; Lipton et al 2003a). 
 Patients with MAP have an increased risk of developing CRC. Malignancy 
has been reported with varying frequencies: one paper reported a prevalence of 
19.47% at 50 years, and 42.89% at 60 years (Lubbe et al 2009); another found that 
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48% of patients with MAP developed CRC with a mean age of diagnosis of 49.7 
years (Sampson et al 2003). It has been suggested that biallelic inactivation of 
MUTYH imparts an overall 93-fold excess risk and that all homozygotes/ compound 
heterozygotes will develop CRC by age 60 (Farrington et al 2005). Win et al (2014) 
estimated that males carrying biallelic MUTYH mutations had a 75.4% risk of 
developing CRC by age 70, and females had a 71.7% risk (Win et al 2014). 
 MAP may also have extra-colonic manifestations, although these are 
generally not part of the characteristic phenotype (Poulsen and Bisgaard 2008). The 
lesions which have been reported include duodenal adenomas and carcinoma, 
fundic gland polyps, stomach cancer, CHRPE, osteomas and breast cancer 
(reviewed in Venesio et al 2012; reviewed in Poulsen and Bisgaard 2008). The 
incidence of extra-intestinal malignancies is almost double that of the general 
population, with a significant increase in ovarian, bladder and skin cancers 
(reviewed in Venesio et al 2012). 
 By 2013, >300 MUTYH variants among MAP patients and/or controls had 
been described (Ruggieri et al 2013). The mutations observed in MUTYH vary 
according to the ethnic group studied, suggesting population specific ancestral 
variants (Dolwani et al 2007; Sieber et al 2003). In Caucasian populations, Y165C 
and G382D are the common mutations (Jones et al 2002; Sampson et al 2003; 
Enholm et al 2003; Sieber et al 2003). These account for 73% of all mutations 
reported and have been described in Swiss (Russell et al 2006), Italian (Gismondi et 
al 2004; Venesio et al 2004), French (Küry et al 2007), Swedish (Kanter-Smoler et 
al 2006; Zhou et al 2005), Canadian (Croitoru et al 2007), Australian (Kairupan et al 
2005), Portuguese (Isidro et al 2004), Czech (Šulová et al 2007), British, American 
and Dutch populations (reviewed in Cheadle and Sampson 2007). There is 
evidence for strong founder effects for these mutations: it is suggested that they 
derive from ancestors who lived between 5-8000 years and 6-9000 years BC 
respectively (Aretz et al 2014). 
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 Numerous other pathogenic variants in MUTYH have been reported, 
including g.1395delGGA in Italians (Gismondi et al 2004), E466X and Y90X in 
Asians (Sampson et al 2003; Jones et al 2002) and R231C in the Japanese (Miyaki 
et al 2005).  
2.1.3 Polymerase Proofreading Associated Polyposis 
(PPAP) 
 PPAP is a relatively recently defined clinical entity. POLE and POLD1 code 
for DNA polymerases with exonuclease (proofreading) activity. Mutations in these 
genes are thought to cause a defect in correcting mispaired bases inserted during 
DNA replication (Palles et al 2013). In 2012, Palles et al undertook whole-genome 
sequencing of probands who had at least 10 colorectal adenomas by age 60, who 
had previously had known Mendelian cancer syndromes excluded in a clinical 
diagnostic setting. They also sequenced several affected relatives (Palles et al 
2013). The group found that a genetic variant, POLE p.Leu242Val, was associated 
with multiple colorectal adenomas and carcinoma (Palles et al 2013). The trait 
showed dominant inheritance, with high penetrance (Palles et al 2013). Another 
variant, POLD1 p.Ser478Asn, predisposed to colorectal tumors, endometrial cancer, 
and possibly brain tumors (Palles et al 2013).  
 In 2014, Valle et al sought to determine the prevalence of these mutations 
in 858 patients with unexplained familial/ early-onset CRC or polyposis. They didn’t 
identify either mutation in any of their CRC cases. However, the POLE p.Leu424Val 
mutation was found in a polyposis family, in which case it had occurred as a de 
novo mutation in the proband. This accounted for 0.52% of the polyposis cases.  
The group also reported a novel variant, POLD1 c.1421T>C (p.Leu474Pro) in a 
MMR-proficient family. This mutation occurs in the proofreading domain of a DNA 
polymerase and was predicted to be pathogenic (Valle et al 2014).  
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 Valle’s group sought to further characterise the phenotypic spectrum of 
patients carrying germline POLE/POLD1 mutations (Bellido et al 2016). They 
sequenced the entire exonuclease domains of POLE/POLD1 in 544 CRC cases 
from 529 families, including those from Valle’s original paper (Valle et al 2014). 
Although no additional POLE mutations were identified, 4 of 6 novel/rare 
nonsynonymous POLD1 variants detected were believed to be pathogenic: 
p.D316H, p.D316G, p.R409W and p.L474P.  The group reviewed the phenotypic 
data from all 69 carriers of POLE/POLD1 mutations that had been reported to date. 
They observed that the associated phenotype was characterised by attenuated/ 
oligo- adenomatous polyposis, with >80% of POLE and >60% of POLD1 mutation 
carriers being diagnosed with >/= 2 adenomas, with an average of 19 lesions. CRC 
was diagnosed in 60-64% of carriers, and brain tumors in 5.8%. Gastroduodenal 
(mostly duodenal) adenomas were identified in 57.1% of carriers who underwent 
gastroduodenoscopies. For patients harbouring POLD1 mutations, the phenotypic 
spectrum was extended to include endometrial  tumors (57.1% of carriers) and 
breast  tumors (14.3% of carriers).  
2.1.4 NTHL1-Associated Polyposis 
A further gene involved in the pathogenesis of colorectal neoplasia is NTHL1. In 
2015 Weren et al carried out whole exome sequencing on 51 patients with multiple 
colorectal adenomas +/- CRC, who had tested negative for APC and MUTYH 
mutations (Weren et al 2015). The group found that 7 individuals were homozygous 
for a NTHL1 nonsense mutation, c.268C>T, which triggers nonsense-mediated 
decay (NMD). The patients harbouring the mutations all had multiple colorectal 
adenomas, ranging from 8-50, and 4 also had multiple CRCs. All 3 affected women 
developed complex endometrial hyperplasia or endometrial cancer. 
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 NTHL1 is a base excision repair gene, and homozygous mutations cause 
an increase in C:G>T:A changes in genes such as APC, p53, KRAS and PI3K 
(Weren et al 2015).   
2.1.5 MSH3-Associated Polyposis 
The most recently identified polyposis syndrome is MSH3-Associated Polyposis 
(Adam et al 2016). Adam’s group performed whole exome sequencing on germline 
DNA extracted from 102 unrelated individuals with unexplained adenomatous 
polyposis. They found two different individuals with different compound 
heterozygous mutations in the mismatch repair gene, MSH3. Both index persons 
had an affected sibling carrying the same mutations. The mutations were associated 
with  tumors which displayed Elevated Microsatellite Alterations At Selected 
Tetranucleotide Repeats (EMAST), a type of microsatellite instability.  
 The phenotypic spectrum in MSH3 mutation carriers was reported to 
include colorectal and duodenal adenomas, CRC, gastric cancer and an early onset 
astrocytoma (Adam et al 2016). 
2.2 Hyperplastic Polyps (HPPs) 
 HPPs are a frequent finding, seen in between 1% and 73% of autopsies 
(Paspatis et al 2001; Williams et al 1982; reviewed in Correa et al 1977). In 
asymptomatic individuals undergoing colonoscopy, HPPs are observed in 21% - 
34% of cases (Forsberg et al 2012; DiSario et al 1991). They are more common in 
males than females, and their prevalence increases with age (Williams et al 1982; 
Williams et al 1980; Correa et al 1977).  
 Until approximately 1990, hyperplastic (or ‘metaplastic’) polyps were 
regarded as a homogeneous group of tumors with no malignant potential (Rosty et 
al 2013a). Since that time, it has been increasingly recognised that hyperplastic 
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lesions are not a single entity – they differ in their morphology and their clinical 
significance, in particular their risk for progressing to carcinoma. In 2010, the World 
Health Organisation published a classification system which subdivides hyperplastic 
lesions into 3 groups based upon their microscopic appearance: Hyperplastic 
Polyps (HPPs), Sessile Serrated Adenomas/Polyps with or without cytological 
dysplasia (SSA) and Traditional Serrated Adenomas (TSA) (reviewed in Rosty et al 
2013a; reviewed in Leggett and Whitehall 2010). 
 It is now known that hyperplastic lesions may be the precursors to CRC 
developing along the serrated pathway of carcinogenesis, which accounts for 
approximately 10% of CRCs (Yamane et al 2014). In contrast to the CRC which 
follow the traditional ‘adenoma carcinoma’ pathway, tumors arising from the 
serrated pathway tend not to display CIN, but instead exhibit MAPK pathway 
activation, through BRAF mutations, and they commonly develop CIMP (Yamane et 
al 2014; Rosty et al 2013a; Leggett and Whitehall 2010).  
2.2.2 Serrated Polyposis Syndrome 
 Although most HPPs are sporadic lesions, there is a condition in which 
patients develop multiple and/or large lesions. One of the first descriptions was in 
1980 by Williams et al (Williams et al 1980). They observed 7 patients, with a mean 
age of 37.4 years, who each had at least 50 lesions throughout their large bowel. At 
that time, the authors concluded that ‘it is impossible to deduce whether or not 
‘metaplastic polyposis’ is a distinct entity. There is no good evidence that it is 
familial in this small series, but the appearance of numerous metaplastic polyps of 
an unusually large size and configuration, predominantly in young males, might 
suggest a specific ‘disease’’.  
 As increasing evidence came to light that there seemed to be a syndrome 
in which patients developed numerous hyperplastic lesions throughout their large 
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bowel, it was named ‘hyperplastic polyposis syndrome’ (HPS). In 2000, a definition 
of HPS was proposed by Jass and Burt in the World Health Organisation 
classification of  tumors (Jass and Burt 2000). This definition was modified in 2010, 
and the disease was officially renamed Serrated Polyposis Syndrome (SPS). It 
appears in the 2010 World Health Organisation classification of  tumors of the 
digestive system (Snover DC et al 2010). In order to meet the diagnostic criteria for 
SPS, patients must fulfil at least one of the following criteria: 
 
1. At least 5 serrated (hyperplastic) polyps proximal to the sigmoid colon, 2 of 
which are >10mm diameter 
2. Any number of serrated polyps proximal to the sigmoid colon in an 
individual who has a first degree relative with serrated polyposis 
3. More than 20 serrated polyps of any size distributed throughout the colon 
 
(reviewed in Rosty et al 2013a; reviewed in Guarinos et al 2012; reviewed in 
Leggett and Whitehall 2010; Snover DC et al 2010) 
 
 It was thought that SPS affected 1 in 3000 asymptomatic individuals 
between the ages of 55 and 64 years (reviewed in Rosty et al 2013b). However, 
most studies report a broad age distribution of the disease (17 to 85 years) with a 
mean age of diagnosis of 47.7-56 years, so it is possible that the prevalence of SPS 
in the general asymptomatic population is higher than 1/3000 (Rosty et al 2013b). 
Recent data suggest that the prevalence may be as high as 1/151 patients who 
have a colonoscopy following a positive faecal occult blood test (reviewed in Rosty 
et al 2013a). 
 SPS shows no sex predilection, and the mean age of diagnosis is 55 years 
(Guarinos et al 2012; Kalady et al 2011). As well as hyperplastic lesions, up to 85% 
of patients also have conventional adenomas present in the bowel (Rosty et al 
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2013a; Rosty et al 2012). Patients with SPS have an increased risk of developing 
CRC, which generally occurs between 50 and 60 years of age (reviewed in 
Guarinos et al 2012). Malignancy is associated with a larger number of polyps, the 
presence of dysplasia (reviewed in Guarinos et al 2012; Yeoman et al 2007) and the 
presence of conventional adenomas in addition to HPPs (Rosty et al 2013b). The 
incidence of CRC in SPS patients varies from 14% to 58% (reviewed in Rosty et al 
2013b; Yeoman et al 2007; Hyman et al 2004; Lage et al 2004) and the incidence is 
greater in females than in males, with a ratio of 2.4:1 (Rosty et al 213b). When 
carcinoma develops in an SPS patient, it is likely to have a proximal location: 64% 
of CRC are identified proximal to the descending colon (Rosty et al 2013b). 
Interestingly, a large proportion of CRCs seen in patients with SPS do not develop 
through the ‘serrated pathway of carcinogenesis’ driven by BRAF mutation (Rosty et 
al 2013b). The tumors show various molecular changes, including those more likely 
to be associated with the traditional adenoma-carcinoma pathway, for example β-
catenin activation and/or overexpression of p53 (Rosty et al 2013b).  
 SPS is thought to be a genetic disease, but the mode of inheritance is 
unclear (reviewed in Guarinos et al 2012). There are papers which report germline 
mutations in the Wnt inhibitor RNF43, an E3 ubiquitin ligase, in individuals and 
families with features of SPS (Yan et al 2017; Taupin et al 2015; Gala et al 2014). 
However, Buchanan et al note that mutations in RNF43 may account for only a 
small proportion of SPS, and that additional genetic risk factors are yet to be 
identified (Buchanan et al 2017).   
2.3 Hamartomatous Polyps 
 Hamartomas are overgrowths of the tissue which is native to the site of the 
lesion. Polyposis syndromes which are characterised by hamartomas include Peutz-
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Jegher’s Syndrome (PJS), Juvenile Polyposis Syndrome (JPS) and Cowden’s 
Disease. 
2.3.1 Peutz- Jegher’s Syndrome (PJS) 
 In 1921, a Dutch physician, Dr. Peutz, first described the combination of 
gastrointestinal polyps and mucocutaneous pigmentation (Peutz 1921). In 1949, Dr. 
Jeghers published an article describing 10 patients who had a combination of 
pigmentation of the oral mucosa/lips/digits, and intestinal polyps (Jeghers et al 
1949). The observations made by Peutz and Jeghers led to the definition of an AD 
syndrome characterised by gastrointestinal polyposis and mucocutaneous 
pigmentation, now known as Peutz-Jeghers Syndrome (PJS) (Westerman et al 
1999). 
 PJS is inherited in an AD manner and has variable penetrance.  It is a rare 
condition, with a prevalence of approximately 1 in 200 000 (reviewed in Omundsen 
and Lam 2012). The disease is characterised by hamartomatous polyps throughout 
the gastrointestinal tract and mucocutaneous pigmentation. Patients present at a 
median age of 11 years, and this is often as a result of a complication of their GI 
polyps, for example intussusception, small bowel obstruction, rectal bleeding or 
volvulus (reviewed in Omundsen and Lam 2012). 
 Approximately 50% of cases of PJS are caused by germline mutations in 
the nuclear serine threonine kinase gene LKB1/STK11 (Jenne et al 1998; reviewed 
in Omundsen and Lam 2012). This gene regulates cell polarisation, growth and 
metabolism. Most mutations are small insertions or deletions, resulting in a 
truncated protein with no kinase activity (reviewed in Omundsen and Lam 2012). 
 Patients with PJS are at increased risk of developing cancer, both at 
gastrointestinal and extra-intestinal sites. The most common  tumors are CRCs, but 
there is also an increased risk of other gastrointestinal (GI) carcinomas 
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(oesophageal, gastric, small bowel and pancreas), breast cancer, ovarian cancer, 
cervical cancer and sex cord  tumors (Hizawa et al 1993; reviewed in Omundsen 
and Lam 2012).  
2.3.2 Familial Juvenile Polyposis Syndrome 
 In 1914, Hertz described four family members who had rectal polyps in 
childhood, the youngest being only 8-years-old (Hertz 1914). That report is regarded 
as the first instance of juvenile polyposis in the medical literature (Calva and Howe 
2009). 
Juvenile polyps are common hamartomatous lesions which occur in the large bowel. 
They are usually solitary and sporadic. If multiple juvenile polyps are present, the 
patient may have Juvenile Polyposis Syndrome (JPS). JPS is an AD disease with 
variable penetrance and which has an incidence of 1 per 100 000 births (reviewed 
in Omundsen and Lam 2012). Patients can present in infancy with GI bleeding, 
intussusception, rectal prolapse or a protein losing enteropathy. Around 15% will 
have an associated congenital birth defect, such as gut malrotation, cardiac and 
cranial abnormalities, cleft palate, polydactyly or genitourinary defects. If 
presentation is as an adult, the patient is likely to suffer from GI bleeding (reviewed 
in Omunsden and Lam 2012). 
 
For a diagnosis of JPS, patients must fulfil one of the following criteria: 
1. More than 5 juvenile polyps of the colon or rectum 
2. Juvenile polyps in other parts of the GI tract 
3. Any number of juvenile polyps and a positive family history 
 
(reviewed in Omundsen and Lam 2012) 
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 Germline mutations in SMAD4 and BMPR1A are seen in JPS, and it is 
suggested that ENG mutations may also have a role (Sweet et al 2005), although 
this is not certain (Howe et al 2007). All of these genes are involved in transforming 
growth factor β (TGFβ) signalling. The TGFβ family of cytokines are growth 
inhibitors, and loss of sensitivity to these factors promotes  tumorigenesis (reviewed 
in Fleming et al 2013). As such, patients with JPS are at increased risk of 
developing CRC (Rozen and Baratz 1982; Järvinen and Franssila 1984; Giardiello 
et al 1991). In additional to colorectal malignancies, patients are also at risk of 
developing gastric and duodenal cancer (reviewed in Omundsen and Lam 2012). 
2.3.3 Cowden’s Syndrome 
 In 1963 Lloyd and Dennis reported a 20-year old female with multiple 
pathologies, including multiple thyroid adenomas, extensive fibrocystic change of 
both breasts and ‘space occupying lesions in the liver and bone’ (Lloyd and Dennis, 
1963). At that time, it was noted that ‘whether this case represents a new familial 
disease….has not been established’ (Lloyd and Dennis, 1963), although they 
named the syndrome ‘Cowden’s Disease’. It is now established that Cowden’s 
Syndrome is an AD disease, affecting approximately 1 in 200 000 births. It is 
commonly diagnosed in the second decade of life, but age of onset may vary from 4 
to 75 years (reviewed in Lam-Himlin et al 2014). Patients develop multiple 
hamartomas in multiple organ systems. Lesions can be found in the skin, GI tract, 
breast, thyroid gland and central nervous system (reviewed in Omunsden and Lam 
2012; Hanssen and Fryns 1995).  
 80% of patients have a germline mutation in the PTEN gene (reviewed in 
Omunsden and Lam 2012). PTEN is a tumor suppressor: its product is a 
phosphatase which negatively regulates the phosphatidylinositol 3-kinase-AKT 
(PI3K) and mammalian target of rapamycin (mTOR) signalling pathways, which are 
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involved in cell growth and proliferation, cell cycle progression and apoptosis 
(reviewed in Lam-Himlin et al 2014). PTEN mutations are involved in the 
pathogenesis of several carcinomas, including breast, endometrial, thyroid, large 
bowel and kidney (reviewed in Lam-Himlin et al 2014). As such, patients with 
Cowden’s Syndrome are at increased risk of these malignancies (Hanssen and 
Fryns 1995). 
2.4 Hereditary Mixed Polyposis Syndrome (HMPS) 
 Hereditary Mixed Polyposis Syndrome (HMPS) is a relatively recently 
defined entity. In 1971, Kaschula described an 11-year-old girl who had profuse 
diarrhoea mixed with blood and mucus. She was found to have polyps throughout 
her large bowel, and the polyps had both adenomatous and juvenile morphologies 
(Kaschula 1971). Over a decade later, in 1987, the term ‘mixed familial polyposis 
syndromes’ was used as the title of a report by Sarles et al (Sarles et al 1987). This 
article described 3 patients, including a father and son, who all had multiple polyps 
of different histopathological types.  
 In HMPS, patients develop multiple polyps with mixed morphologies. This 
is an AD disease, and patients may have adenomas, hyperplastic polyps and 
hamartomatous polyps. There is a high risk of developing CRC (Jaeger et al 2012). 
The disease is caused by a duplication spanning part of the SCG5 gene and a 
region upstream of the GREM1 locus. This duplication causes increased expression 
of GREM1, which acts as a bone morphogenetic protein (BMP) antagonist. The 
subsequent reduction in BMP signalling is thought to play a role in  tumorigenesis 
(Jaeger et al 2012). 
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3. Clinical Management of Patients with Colorectal 
Polyposis  
 It has been common clinical practice for patients with >10 colorectal 
adenomas to be referred to a regional genetics centre for genetic counselling and 
for consideration of diagnostic analysis of the APC and/or MUTYH genes. The 
diagnostic testing carried out will depend upon the individual’s phenotype and their 
family history.  
 Up to 90% of patients with a phenotype of typical FAP have a pathogenic 
APC germline mutation identified through sequencing of coding exons and 
deletion/duplication analysis via multiplex ligation-dependent probe amplification 
(MLPA) (Spier et al 2012). Of those with a phenotype of AFAP, APC or biallelic 
MUTYH germline mutations are detected in only 20-50% of cases (Spier et al 2012).  
4.  ‘Unexplained’ Colorectal Polyposis  
 Since 1991, when APC was recognised as the causative gene of FAP 
(Groden et al 1991; Joslyn et al 1991; Kinzler et al 1991; Nishisho et al 1991), 
several screening and diagnostic strategies have been developed to identify 
pathogenic APC mutations (Scott et al 2001) in patients with multiple colorectal 
adenomas. These have included denaturing gradient gel electrophoresis analysis 
(DGGE) (Scott et al 2001; Olschwang et al 1993), ribonuclease protection analysis 
(Miyoshi et al 1992), single strand conformation polymorphism analysis (SSCP) 
(Cottrell et al 1992; Groden et al 1993), heteroduplex analysis (HA) (Cottrell et al 
1992) and the protein truncation test (PTT)/ in vitro synthesised protein assay 
(IVSP) (Powell et al 1993). The characterisation of a genetic mutation identified 
through screening requires DNA sequencing. Sanger sequencing has been the gold 
standard of sequencing for several decades, and until very recently was the main 
approach used for the molecular diagnosis of colorectal polyposis. In the last few 
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years, next-generation sequencing (NGS) technologies have progressively replaced 
Sanger sequencing.  
 Genetic diagnostic protocols used in patients with polyposis typically 
include sequencing of APC and/or MUTYH and dosage analysis of the genes using 
a technique such as MLPA. These approaches could miss pathogenic variants 
located in promoter regions, deep within introns (Spier et al 2012) or in untranslated 
regions (UTRs), which may have effects on gene expression mediated through 
effects on transcription, mRNA splicing or mRNA stability. Similarly, diagnostic 
protocols may miss low frequency variants in patients with somatic mosaicism. Most 
Many diagnostic protocols would also not identify epigenetic phenomenon such as 
promoter methylation, they would not detect mutations in genes which are 
established but rare causes of polyposis (e.g. POLE/POLD1) and they would also 
not identify novel polyposis genes. 
4.1 Promoter Variants and Allelic Imbalance (AI)  
 The APC gene has two promoter regions, 1A and 1B (reviewed in Rohlin et 
al 2011). The major transcript is initiated by the major promoter, 1A (reviewed in 
Charames et al 2008). It is possible that genetic variants occurring in these 
promoters could lead to reduced gene expression, therefore predisposing to  tumor 
formation. Such variants might not be identified through standard genetic 
diagnostics as the promoter is not typically included in diagnostic sequencing 
protocols. 
 There are several reports of APC promoter mutations in the literature. 
However, these typically describe deletions, which would be detected through 
diagnostic MLPA (Yamaguchi et al 2016; Pavicic et al 2014; Rohlin et al 2011; 
Charames et al 2008). There is a paucity of literature describing APC promoter point 
mutations or methylation as a cause of colorectal polyposis.   
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 Allelic imbalance (AI) refers to a situation in which the two alleles of a given 
gene are expressed at different levels in a given cell (Wagner et al 2010). It can 
occur due to epigenetic inactivation of one of the alleles, or because of genetic 
variation in regulatory regions (Wagner et al 2010). AI can involve complete 
inactivation of one allele, for example in parent-of-origin imprinting, when a specific 
allele at a given locus is silenced through epigenetic mechanisms depending on 
whether it was inherited from the mother or father (Wagner et al 2010). Allele 
expression can also be partially reduced, which can occur when different alleles 
have differing affinities for transcription factors (Wagner et al 2010), or 
through cis- acting genetic variants, for example in promoters (Wagner et al 2010).  
  As well as being important in normal phenotypic variation, AI can also 
contribute to  tumorigenesis. There is some evidence that BRCA1 and BRCA2 AI 
plays a role in the pathogenesis of ovarian and breast cancer (Chen et al 2008; 
Shen et al 2011). Whilst only a small number of studies have considered APC AI in 
the context of colorectal neoplasia, those which have been performed have found it 
may make an important contribution. As early as 1993, Powell et al (Powell et al 
1993) used an allele-specific expression assay to show that 3/11 APC NMI patients 
with clinical FAP had significantly reduced expression of one APC allele. In 1999 
Laken et al (Laken et al 1999) used monoallelic mutation analysis (MAMA) to reveal 
that 7/9 APC NMI patients had reduced/no expression from one of their APC alleles. 
More recently Yan et al (2002) identified a patient with colorectal  tumors who was 
known to have reduced levels of the APC protein. The group quantified the relative 
levels of mRNA transcripts from each APC allele using Digital-SNP. They found that 
gDNA yielded the expected 50% allelic ratio, but that cDNA from lymphoblastoid 
cells showed a skewed distribution, with a ratio of approximately 66% (Yan et al 
2002). Linkage analysis showed that the allele whose mRNA was expressed in 
lower amounts was the one linked to disease (Yan et al 2002). Further work 
confirmed that the skewed allelic ratio was also present in 4 affected family 
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members, but that the ratio was normal in 24 unrelated unaffected individuals. The 
group continued to investigate expression levels of APC: in four patients with clinical 
FAP who had no abnormalities with the in vitro synthesised protein assay (IVSP) or 
allele sequencing, one was found to have an abnormal 71% allelic ratio in cDNA. 
When  tumors from the patients with AI were studied, 30/38 had LOH of APC, and in 
29 of these cases, it was the normal allele which had been lost. Yan et al concluded 
that an allele which causes a decrease in transcript levels can result in a 
predisposition to severe disease, but that there needs to be a second hit to the 
normal allele for a disease to manifest (Yan et al 2002). Interestingly the cause of 
the decreased expression was not determined: the sequences of the coding 
regions, promoter and 3’UTR were normal, so the group assumed that the 
pathogenic variant must lie within an intron or upstream of the gene (Yan et al 
2002). These early findings regarding APC AI have been supported by Castellsagué 
et al (2010). Of 23 APC/MUTYH NMI polyposis families who were heterozygous for 
rs2229992, 2 were shown to harbour APC AI. The AI in one family was suggested 
to result from promoter variants (Castellsagué et al 2010). 
4.2 Intronic Variants 
 Intronic mutations may affect RNA splicing and introns are not screened as 
part of most routine genetic diagnostic protocols. In 2000 Su et al sought to identify 
novel intragenic rearrangements of APC in patients with a clinical phenotype of FAP 
or AFAP. They found four germline APC mutations, one of which was a deletion 27-
1627bp downstream of exon 14, which was replaced with a novel sequence of 
about 180bp. The deletion was completely within intron 14, but it affected the 
splicing of exon 14 (Su et al 2000). In 2010 Tuohy et al used Southern Blot analysis 
of the APC gene to identify a 1.4kb deletion within intron 14 in a family with AFAP. 
Subsequent PCR amplification from exon 13 to exon 15 of cDNA showed that the 
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intronic deletion resulted in abnormal splicing, and that exon 14 was deleted. This 
caused a frameshift and protein truncation at codon 673 of the normal reading 
frame resulting in a truncated product that lacked all of the β-catenin, microtubule 
and EB-1 binding domains (Tuohy et al 2010).  
 In 2012 transcript analysis in a sample of 125 mutation negative patients 
with colorectal adenomatous polyposis found that 8% had a reproducible aberrant 
transcript pattern, suggesting an intronic mutation at a genomic level (Spier et al 
2012). 80% of these were found to have transcript insertions between two exons 
originating from exonised sequences deep within the corresponding intron (Spier et 
al 2012). All pseudoexons were predicted to result in out-of-frame transcripts with 
premature stop codons (Spier et al 2012). In those patients who had insertions, the 
underlying genomic mutations were identified: they comprised 3 different 
heterozygous point mutations (c.532-941G>A, c.1408+731C>T, c.1408+735A>T) 
which activated cryptic splice sites. A pre-existing complementary cryptic splice site 
was predicted at the other end of the insertion (Spier et al 2012).  
4.3 Untranslated Region (UTR) Variants 
 A pre-RNA molecule undergoes several steps of processing before it 
becomes a functional mRNA molecule (Mignone et al 2002). Mature mRNA consists 
of a 5’ untranslated region (5’UTR), a coding region, and a 3’ UTR (Mignone et al 
2002). UTRs, particularly 3’UTRs, have multiple roles in the post-transcriptional 
regulation of gene expression, including effects on mRNA transport out of the 
nucleus, translation efficiency, subcellular localisation and mRNA stability (reviewed 
in Mignone et al 2002). In addition to normal physiological intracellular effects, there 
is increasing evidence that UTR variants can be involved in disease, for example an 
expanded number of trinucleotide repeats in the 3’UTR of the DMPK gene is 
thought to play a role in the pathogenesis of in myotonic dystrophy (Conne et al 
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2000), and a somatic 5’UTR variant has been reported to reduce translation 
efficiency of BRCA1 in a highly aggressive sporadic breast cancer (Signori et al 
2001).  
 In the context of colorectal neoplasia, Wilding et al have shown that in 
microsatellite unstable cancer, deregulation of mRNA stability due to mutations in 
regulatory 3’UTR sequences can lead to a marked difference in gene expression 
profiles when compared to microsatellite stable  tumors (Wilding et al 2010).  
4.4 Mosaicism 
 A mosaic is an individual who has at least two genetically different cell lines 
despite developing from a single zygote. Mosaic mutations may be missed with 
standard mutation diagnostic techniques, for example if they occur at a low 
frequency within the individual or if they do not occur in the part of the body which is 
being analysed. 
 It is reported that somatic mosaicism can occur in 10-20% of sporadic 
cases of FAP (reviewed in Rohlin et al 2009; Hes et al 2008; Aretz et al 2007). The 
timing at which an APC mutation occurs will have an important bearing on the 
patient’s phenotype: if it arises in a single colonic epithelial stem cell, the only 
consequence will be adenomatous polyps in the segment of the colon that becomes 
populated with descendants of the stem cell (Tuohy and Burt 2008). At the other 
extreme, if the mutation occurs early in embryogenesis, it may be found in all three 
germ cell layers. This would result in multiple clinical manifestations seen 
throughout multiple organ systems, potentially including mutations in reproductive 
cells, which could then be passed on to future generations (Tuohy and Burt 2008).  
 Depending on the frequency of the mutation, it is likely that a significant 
proportion will be missed using current diagnostic sequencing protocols and DNA 
extracted from whole blood. Rohlin et al (2009) carried out a study to evaluate the 
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different mutation screening/diagnostic techniques in terms of their sensitivity in 
detecting mosaicism. They looked at Sanger sequencing, single-strand 
conformation polymorphism (SSCP)/heteroduplex analysis (HA), the protein 
truncation test (PTT), denaturing high performance liquid chromatography (DHPLC) 
and massively parallel sequencing. A total of 9 mutations were addressed – 8 in 
APC and 1 in NF2. The group constructed 7 artificial mosaics in APC through serial 
dilutions of DNA, with a non-mosaic heterozygous mutation being defined as 100%. 
The two remaining samples were from naturally occurring mosaics. All of the 
dilutions of all of the mutations were analysed with SSCP, DHPLC and Sanger 
sequencing. Three were included in the PTT assay (these were mutations in exon 
18, which is readily screened by PTT). Only four artificial mosaics, at various 
concentrations, and both natural mosaics underwent massively parallel sequencing, 
due to cost limitations. The group found that SSCP and DHPLC were able to detect 
mutant alleles at frequencies between 5% and 25%, whereas Sanger sequencing 
required frequencies between 15% and 50% for detection. The mutations included 
in the PTT assay were detected at frequencies between 10 and 100%. The Genome 
Sequencer FLX was used for massively parallel sequencing, and this achieved 
coverage between 648 and 8313 reads. Mutations frequencies as low as 1% could 
be detected, but this required a high coverage (Rohlin et al 2009). 
 The results from this study showed that Sanger sequencing, which has 
been commonly used in a diagnostic setting, was the least sensitive method at 
detecting mosaics. Dependent upon the type of mutation being analysed, this 
technique may require mutation frequencies as high as 50% in order for them to be 
detected (Rohlin et al 2009). 
 Genetic testing in the diagnostic setting is usually carried out on DNA 
extracted from whole blood. For some patients, a mosaic mutation may only be 
present in colonic tissue so will not be detectable through testing blood-derived DNA 
(Jansen et al 2017). 
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4.5 The Involvement of Additional Genes 
 Standard diagnostic protocols carried out in the context of adenomatous 
colorectal polyposis typically examine the APC and MUTYH genes, although an 
increasing number of laboratories are screening DNA for the recurrent mutations in 
POLE and POLD1. It is only in recent years that the pathogenic effects of mutant 
POLE, POLD1, NTHL1 and MSH3 have been discovered. It is therefore feasible 
that there may be further genes involved in the development of heritable colorectal 
polyposis, which are yet to be identified.  
 Furthermore, mutations in genes such as APC, MUTYH, POLE, POLD1, 
NTHL1 and MSH3 are all highly penetrant. It may be the case that some patients 
with unexplained colorectal polyposis have a phenotype which results from the 
complex interplay of several low/moderate penetrance genetic variants. 
5. Summary 
Colorectal carcinoma (CRC) is the third most common cancer in men and the 
second most common cancer in women (Ferlay et al 2013).  Most CRCs occur 
sporadically, but in approximately a third of patients, hereditary factors are important 
(reviewed in Mishra and Hall 2012; Burt 2007). Some patients with an inherited 
predisposition to CRC will be diagnosed with a ‘genetic polyposis syndrome’ such 
as FAP, MAP, PPAP, NTHL1-Associated Polyposis, MSH3-Associated Polyposis or 
a hamartomatous polyposis syndrome. It is important to identify these patients, and 
to define the mutations causing their polyposis, so that the individuals and their 
relatives can be managed appropriately.  
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